Univest
Univest
  • Markets

3 Ferro Alloys and Power Company, Pharmaceuticals Maker and Electrical Goods Maker Stocks With a Strong Future Roadmap: Sarda Energy, Marksans Pharma and Havells India

  • November 16, 2026
  • Posted by: Chaitanya Auti
  • Category: Best Stocks
No Comments
3 Ferro Alloys and Power Company, Pharmaceuticals Maker and Electrical Goods Maker Stocks With a Strong Future Roadmap: Sarda Energy, Marksans Pharma and Havells India

Sarda Energy, Marksans Pharma and Havells India: ROE of 13.8% to 17.9% and FY22 to FY26 revenue CAGR of 10.6% to 18.6%. Prices as of 13 Nov 2026.

Quick Answer

The three ferro alloy, pharma and electrical stocks to watch are Sarda Energy, Marksans Pharma and Havells India. Their return on equity ranges from 13.8% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 18.6%. Havells India has the highest return on equity at 17.9%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.

Ferro alloy, pharma and electrical stocks let investors follow companies that serve a growing part of the Indian economy. Sarda Energy, Marksans Pharma and Havells India cover a ferro alloys and power company, a pharmaceuticals maker and an electrical goods maker.

This list covers three ferro alloy, pharma and electrical stocks with complete current figures: Sarda Energy, Marksans Pharma and Havells India. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Ferro Alloy, Pharma and Electrical Stocks?
  • Ferro Alloy, Pharma and Electrical Stocks at a Glance
  • Why Do Ferro Alloy, Pharma and Electrical Stocks Have a Strong Roadmap in India?
  • Why Sarda Energy Features Among These Ferro Alloy, Pharma and Electrical Stocks
  • Why Marksans Pharma Features Among These Ferro Alloy, Pharma and Electrical Stocks
  • Why Havells India Features Among These Ferro Alloy, Pharma and Electrical Stocks
  • Sarda Energy vs Marksans Pharma vs Havells India on Key Financials
  • Key Risks to Check Before Investing in Ferro Alloy, Pharma and Electrical Stocks
  • Final Thoughts on Ferro Alloy, Pharma and Electrical Stocks
    • What are ferro alloy, pharma and electrical stocks?
    • Which ferro alloy, pharma and electrical stocks are covered in this list?
    • Why do ferro alloy, pharma and electrical stocks have a strong future roadmap in India?
    • How has Sarda Energy performed financially?
    • How has Marksans Pharma performed financially?
    • How has Havells India performed financially?
    • What risks should investors check before buying ferro alloy, pharma and electrical stocks?
    • Is this list of ferro alloy, pharma and electrical stocks investment advice?

What Are Ferro Alloy, Pharma and Electrical Stocks?

Ferro alloy, pharma and electrical stocks are listed companies that make ferro alloys, steel and power for industry, make and sell medicines for India and global markets, and make fans, switches, cables and home appliances. Their earnings depend on steel demand, medicine demand and home electricals demand.

Ferro Alloy, Pharma and Electrical Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Sarda Energy 444.3 16,079 14.0 22.4 15.0 0.36
Marksans Pharma 318.5 12,994 24.9 35.7 13.8 0.11
Havells India 1,161 68,928 42.2 44.3 17.9 0.03

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing ferro alloy, pharma and electrical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Ferro Alloy, Pharma and Electrical Stocks Have a Strong Roadmap in India?

Ferro alloy, pharma and electrical stocks have a strong roadmap in India because strong steel output, wider access to quality medicines and rising household appliance use keep widening the market for these companies.

  • Ferro alloys. Steel makers need alloy inputs.
  • Pharmaceuticals. Patients need quality medicines.
  • Electrical goods. Homes buy more appliances.

Why Sarda Energy Features Among These Ferro Alloy, Pharma and Electrical Stocks

Among the ferro alloy, pharma and electrical stocks on this list, Sarda Energy and Minerals is a Raipur-based integrated company producing ferro alloys, sponge iron, steel billets and power, supported by its own mines.

In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%.

Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4.

Roadmap: The company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.

What to watch: Track capacity additions, captive mine output and power plant performance.

Why Marksans Pharma Features Among These Ferro Alloy, Pharma and Electrical Stocks

Among the steel input maker, medicine maker and switch shares on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.

The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.

Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.

Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

What to watch: Track export growth, new product approvals and plant utilisation.

Why Havells India Features Among These Ferro Alloy, Pharma and Electrical Stocks

Among the three companies on this list, Havells India is a leading electrical products company that sells fans, lighting, switchgear, wires and cables, and consumer appliances, along with Lloyd air conditioners.

Revenue rose from Rs 14,099 crore in FY22 to Rs 23,022 crore in FY26, a compound annual growth rate of 13.0%. Net profit grew from Rs 1,196 crore in FY22 to Rs 1,689 crore in FY26, which works out to a compound annual growth rate of 9.0%.

In the June 2026 quarter, revenue grew 19.0% year on year to Rs 6,572 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 68,928 crore. The stock trades at a P/E of 42.2, below the industry P/E of 44.3.

Roadmap: The company sells through a wide dealer network and keeps adding premium products and new categories such as air conditioners and water heaters. Capacity expansion in cables and appliances supports future growth.

What to watch: Check growth in the cables and Lloyd air conditioner businesses.

Sarda Energy vs Marksans Pharma vs Havells India on Key Financials

The table below sets the three ferro alloy, pharma and electrical stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Sarda Energy 3,964 5,928 10.6% 1,063 17.9%
Marksans Pharma 1,533 3,033 18.6% 420 13.8%
Havells India 14,099 23,022 13.0% 1,689 7.3%

Havells India posts the highest return on equity in this group at 17.9%. Havells India has the largest FY26 revenue at Rs 23,022 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with ferro alloy, pharma and electrical stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Sarda Energy 1,713 1,717 0.2%
Marksans Pharma 626 866 38.5%
Havells India 5,525 6,572 19.0%

Key Risks to Check Before Investing in Ferro Alloy, Pharma and Electrical Stocks

Every theme carries risks that deserve a check before any decision. For these ferro alloy, pharma and electrical stocks, the main points are: Long-term steel input maker, medicine maker and switch shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Commodity prices. Selling prices follow global and domestic markets.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter ferro alloy, pharma and electrical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Ferro Alloy, Pharma and Electrical Stocks

Ferro alloy, pharma and electrical stocks reward investors who follow demand trends, order books and margins together. Sarda Energy, Marksans Pharma and Havells India each have a clear plan to grow. Based on the 13 November 2026 close, Sarda Energy trades at Rs 444.3, Marksans Pharma at Rs 318.5 and Havells India at Rs 1,161. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these ferro alloy, pharma and electrical stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track ferro alloy, pharma and electrical stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are ferro alloy, pharma and electrical stocks?

Ans. Ferro alloy, pharma and electrical stocks are listed companies that make ferro alloys, steel and power for industry, make and sell medicines for India and global markets, and make fans, switches, cables and home appliances. Their earnings depend on steel demand, medicine demand and home electricals demand. This list looks at three of them, Sarda Energy, Marksans Pharma and Havells India, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.

Which ferro alloy, pharma and electrical stocks are covered in this list?

Ans. This list covers Sarda Energy, Marksans Pharma and Havells India. Based on the 13 November 2026 close, Sarda Energy traded at Rs 444.3, Marksans Pharma at Rs 318.5 and Havells India at Rs 1,161. Their return on equity ranges from 13.8% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 18.6%.

Why do ferro alloy, pharma and electrical stocks have a strong future roadmap in India?

Ans. Ferro alloy, pharma and electrical stocks have a strong roadmap in India because strong steel output, wider access to quality medicines and rising household appliance use keep widening the market for these companies. The main drivers are as follows. Ferro alloys. Steel makers need alloy inputs. Pharmaceuticals. Patients need quality medicines. Electrical goods. Homes buy more appliances. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sarda Energy performed financially?

Ans. Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%. In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4. Looking ahead, the company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.

How has Marksans Pharma performed financially?

Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

How has Havells India performed financially?

Ans. Revenue rose from Rs 14,099 crore in FY22 to Rs 23,022 crore in FY26, a compound annual growth rate of 13.0%. Net profit grew from Rs 1,196 crore in FY22 to Rs 1,689 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 6,572 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 68,928 crore. The stock trades at a P/E of 42.2, below the industry P/E of 44.3. Looking ahead, the company sells through a wide dealer network and keeps adding premium products and new categories such as air conditioners and water heaters. Capacity expansion in cables and appliances supports future growth.

What risks should investors check before buying ferro alloy, pharma and electrical stocks?

Ans. Investors should check a few risks before buying ferro alloy, pharma and electrical stocks. Commodity prices. Selling prices follow global and domestic markets. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of ferro alloy, pharma and electrical stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



alloys and power Best Stocks ferro alloy formulations and home electricals stocks Havells India Marksans Pharma medicine maker and switch shares pharma and electrical stocks Sarda Energy steel input maker

Leave a Reply Cancel reply